Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535363 · ClinicalTrials.gov registry record · Phase 1
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
A Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 2
- Study locations
NCT03535363: Completed Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Case Comprehensive Cancer Center.
NCT03535363 is a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 6 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03535363, a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
Primary Outcome
To determine the safety, tolerability and maximum tolerated dose of Osimertinib, when administered in combination with SRS in patients with EGFR positive NSCLC with brain metastases.
Conditions Studied
Interventions
- DRUG Osimertinib
Study Locations (2)
Florida
- Maimi Cancer Institute - Baptist Health South Florida - Miami
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-10-26 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 1 |
What the finished NCT03535363 record still lists
NCT03535363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Osimertinib is the first listed.
NCT03535363 reports a single indexed study location in Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT03535363 about?
NCT03535363 is a clinical study titled "Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC". Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
What is the current status of trial NCT03535363?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2018-10-26. Estimated completion is 2022-04-01.
What conditions does trial NCT03535363 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.
What interventions are being tested in trial NCT03535363?
The interventions under investigation include: Osimertinib (DRUG).
Who is sponsoring clinical trial NCT03535363?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03535363 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03535363's enrollment target sits among peer trials
6 449th of 454 higher than 3 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI